oncology

Despite hype, private payers slow to adopt oncology value-based modelsOncology Institute’s Dawn Holcombe, MBA, FACMPE, ACHE, shares her views on the OCM program, what CAR T-cell therapy means for the future of reimbursement, and some epic predictions.
FDA approves first drug for breast cancer with BRCA geneFDA approved the first drug to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation.
CAR T-cell therapies in treating lymphoma: Pros and consCatherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.
Top 3 new drug approvalsHere are 3 of the top new drug approvals in late December and early January.
Top 5 pipeline drugs for 2018
Top 5 pipeline drugs for 2018New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
Three things health execs need to know about CAR T-cell therapyHere’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
What oncologists say about new cancer treatment optionsA new report from Cardinal Health Specialty Solutions gives behind-the-scenes perspectives from oncologists about CAR-T cell therapies, biosimilars and AML therapies (or genomic medicines)
New treatment for advanced kidney cancer approved
New treatment for advanced kidney cancer approvedFDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).
Four therapeutic areas to watch in 2018
Four therapeutic areas to watch in 2018Prepare for major pipeline developments in diabetes, autoimmune disorders, oncology, and COPD.
Treating frail elderly patients with multiple myeloma requires different approachTransplant eligibility issues and drug regimen options raise difficult questions when treating older multiple myeloma patients.